Browse our latest media releases, coverage, videos, events and presentations for Atturos...
Atturos Led Consortium Awarded €1.57m to Develop PERSONA
22nd April 2021
Atturos is delighted to announce it has secured €1.57m funding from the third round of the Disruptive Technologies Innovation Fund. In collaboration with Agilent Technologies Ireland, Neoteryx and UCD, the consortium will develop the first innovative plasma sampling device for inflammatory diseases. We are excited to move PERSONA (Patient Centric Sampling for a New Diagnostic Pathway) forward, and look forward to updating you all soon with further information!
Atturos Christmas Tree Lights Switch On!
1st December 2020
We all know it's been a challenging year, so we used the 1st of December as an excuse to decorate the office, put on our festive jumpers and switch on the Atturos office Christmas tree lights! Thanks to our fantastic research assistant Joy for doing the honours.
Patent granted for OCProDx in the United States of America
17th November 2020
Following the grant of the “Prostate Cancer Biomarkers” patent in Europe, Atturos have now been granted a US wide patent (US 15/106,582) derived from International patent application (PCT/EP2014/078914).
Scientific Paper published in BMC Clinical Proteomics
21st October 2020
Read our latest publication "A robust multiplex immunoaffinity mass spectrometry assay (PromarkerD) for clinical prediction of diabetic kidney disease". This work represents a collaborative effort between the Atturos Team, Proteomics International (Perth) and Sydney Mass Spectrometry.
New Atturos Website Launched
25th September 2020
As our team and portfolio are quickly expanding, our website needed to grow with us... welcome to the new look website! If you have any feedback, please let us know!
100 Hot Start Ups – Sunday Business Post
30th September 2019
Atturos Ltd is delighted to be recognised amongst The Sunday Business Post’s latest list of Irish entrepreneurial companies.
Proteomics International and Atturos Partner to Target Diagnostics in Europe
19th September 2018
Proteomics International and Irish clinical diagnostics company Atturos have signed a Memorandum of Understanding that will see the companies join forces to develop novel diagnostic tests for the European region.
Atturos Host Clinical and Technical Brainstorming Sessions with Key Opinion Leaders
16th May 2016
Last Friday May 13th Atturos hosted a Clinical and Technical Brainstorming session in NovaUCD as part of our market analysis to obtain and evaluate customer and end user attitudes towards the OCProDx test...
Prostate Cancer Review Selected as Feature Article
18th January 2021
BMC Clinical Proteomics, part of Springer Nature, selected "Clinical proteomics for prostate cancer" as the feature article for January and February 2021. The review, led by Atturos CSO Steve Pennington, discusses high throughput proteomic technologies as a potential solution for the current challenges faced in diagnosing and treating prostate cancer.
Atturos founder and CSO Stephen Pennington gives key note at PSI 2020
22nd November 2020
Steve presented on the "Development and Delivery of Advanced Protein Tests for an Era of Precision Medicine". For further information on PSI 2020 visit their website!
Atturos Completes Business Case Analysis of Novel Test to Discriminate Psoriatic Arthritis from Rheumatoid Arthritis
16th November 2020
The Atturos management team have undertaken and completed a business case analysis for the commercial feasibility of a serum protein assay – PsARADx. The assay is protected under UCD patent application WO 2020/025721and provides “A method of diagnosing or prognosing psoriatic arthritis”. The analysis undertaken included engagement with key stakeholders. Atturos is now in negotiations with UCD to acquire a license to the patent.
HUPO’s Proteome Project releases the 10-year High‑Stringency Blueprint of the Human Proteome
16th October 2020
Atturos founder, Steve Pennington, and Senior Scientist, James Waddington, played a key role in publication of the Human Proteome Project’s blueprint of the Human Proteome 'A high-stringency blueprint of the human proteome'.
Atturos joins the SOPHIA international research consortium
2nd June 2020
New €16 million EU and industry-supported international research consortium aims to improve obesity treatment and change the narrative around obesity
Twenty-nine leading partners from civil society, academia and industry in 12 countries have joined forces to better understand obesity and optimise future treatment
Poster Presented at the 18th Annual HUPO Congress in Adelaide, Australia.
18th September 2019
Orla Coleman (Atturos) and Scott Bringans (PILL) present the poster "PromarkerD as an immunoaffinity mass spectrometry assay for diabetic kidney disease"
European wide patent granted for OCProDx
17th July 2019
Atturos are pleased to announce that the European patent filing (EP3084444) derived from International patent application (PCT/EP2014/078914) for “Prostate Cancer Biomarkers” has been granted. The patent supports the on-going protection of OCProDx.
Atturos partners with SCREENED H2020 consortium
16th January 2019
The new European collaborative project SCREENED aims to develop three-dimensional (3D)
cellbased in vitro tests to better characterize the effects of endocrine disruptors on thyroid gland function.
OCProDx showcased at Enterprise Ireland’s Big Ideas 2018
5th September 2018
Twelve start-ups pitched their new technology solutions to investors at the 10th annual innovation showcase event BIG IDEAS. Atturos were shortlisted and presented OCProDx to an invited audience of Irish research and business communities
Atturos presents at Oxford Global 13th Annual Biomarkers Congress in Manchester, U.K.
16th February 2018
Steve Pennington invited to join Oxford Global Biomarkers Directors Club and presents at 13th Annual Congress, Manchester, U.K.
Agilent Technologies Lunchtime Workshop at MSACL Annual Conference, Palm Springs, California, U.S.A.
24th January 2018
Atturos development and delivery of MassSpec based multiplexed biomarker assays was presented by Steve Pennington at a lunchtime workshop hosted by Agilent at the Mass Spectrometry Applications to the Clinical Lab 10th Annual Conference Palm Springs, California, U.S.A.
Meeting Brief: The 2nd Annual John Fitzpatrick Prostate Cancer Conference 2016
25th April 2016
Members of the Atturos team attended the 2nd Annual John Fitzpatrick Prostate Cancer Conference last week in the Aviva Stadium in Dublin.
Atturos licenses patent WO 2020/025721 “A method of diagnosing or prognosing psoriatic arthritis” from University College Dublin
11th January 2021
Atturos are pleased to announce that following the completion of a business case analysis, it has negotiated a worldwide exclusive license agreement for patent WO 2020/025721 “A method of diagnosing or prognosing psoriatic arthritis” from University College Dublin. The patent underpins the serum protein ‘PsARADx’ assay which can discriminate patients with psoriatic arthritis from those with rheumatoid arthritis. Atturos is looking forward to beginning the next steps in developing the assay which has the potential to improve psoriatic arthritis patient outcomes.
Review Article Published in BMC Clinical Proteomics
20th November 2020
Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management
Clinical Research Application Note Published in Collaboration with Agilent Technologies
30th October 2020
Read our latest application note "From Nanoflow to Standard Flow LC/MS for Routine Quantitative Plasma Proteomics in Diabetic Kidney Disease Research".
Review Article Published in the
Journal of Molecular Sciences
21st May 2020
SCREENED: A Multistage Model of Thyroid Gland Function for Screening Endocrine-Disrupting Chemicals in a Biologically Sex-Specific Manner
Atturos Presents at CPSA, USA
7th November 2019
Founder and Chief Scientific Officer Prof. Stephen Pennington presents Atturos work at the Clinical and Pharmaceutical Solutions through Analysis Symposium in Philadelphia, Pennsylvania, U.S.A on the 28th of October 2019.
PromarkerD validation study sees transfer to Atturos for EU launch
16th September 2019
Atturos begins collaboration with Merck KGaA, Darmstadt, Germany
23rd April 2018
Atturos is pleased to announce it has begun a significant collaboration with Merck KGaA. “The projects sees Atturos developing important LC-MS workflows for Merck KGaA and marks what both companies hope will be a series of ongoing collaborative projects” notes Dave Corr, CEO Atturos Ltd.
Stephen Pennington hosts HUPO 2017 as Lead Organiser
17th September 2017
Atturos Founder and CSO Stephen Pennington hosts the 16th Human Proteome Organisation World Congress in Dublin.
EAU 2016 Annual Meeting
16th March 2016
As part of our continuous clinical and market research efforts Atturos CEO Stephen Pennington attended the European Association of Urology Annual Meeting this past weekend.